Answers are grounded in this paper and cite their sources.
With the frequent emergence of new infectious diseases and the growing demand for precision medicine, the limitations of traditional vaccines are becoming increasingly apparent. Virus-like particles (VLPs) have become a key platform for the development of next-generation vaccines due to their combination of structural characteristics typical of natural viruses and a favorable safety profile. From the perspective of synthetic biology, this article reviews the working principles, production processes, and key construction technologies of VLP vaccines, with a focus on research progress regarding chassis protein design, engineering modification of antigen modules, optimization of linkage systems, and enhancement of structural stability. Meanwhile, the development status of marketed VLP vaccines, such as those for hepatitis B virus (HBV), hepatitis E virus (HEV), and human papillomavirus (HPV) is summarized, and the application of VLP vaccines currently in clinical research, including those for influenza, COVID-19, and HIV is analyzed. The results demonstrate that synthetic biology has significantly enhanced the programmability, immunogenicity, and development efficiency of VLP vaccines, driving their evolution toward multivalent, intelligent, and personalized forms. However, issues such as complex antigen display, large-scale production, and the evaluation of long-term protective efficacy remain to be addressed. Future research could further integrate AI-driven protein design, novel expression systems, and precision delivery technologies to advance the clinical translation and industrial application of VLP vaccines.
No takes yet. Share an insight, caveat, or question.
Yongcan Zhou (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: